Biomarin Pharmaceutical Inc (NASDAQ: BMRN) is 8.34% higher on its value in year-to-date trading and has touched a low of $60.63 and a high of $94.85 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The BMRN stock was last observed hovering at around $71.19 in the last trading session, with the day’s gains setting it 0.02%.
Currently trading at $71.21, the stock is 5.41% and 8.30% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.18 million and changing 0.03% at the moment leaves the stock -3.73% off its SMA200. BMRN registered -18.82% loss for a year compared to 6-month loss of -22.26%.
The stock witnessed a 13.27% gain in the last 1 month and extending the period to 3 months gives it a 9.49%, and is 3.02% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 2.18% over the week and 2.73% over the month.
Biomarin Pharmaceutical Inc (BMRN) has around 3040 employees, a market worth around $13.59B and $2.84B in sales. Current P/E ratio is 32.38 and Fwd P/E is 17.31. Profit margin for the company is 15.03%. Distance from 52-week low is 17.45% and -24.92% from its 52-week high. The company has generated returns on investments over the last 12 months (6.79%).
with sales reaching $741.1M over the same period.The EPS is expected to grow by 43.47% this year, but quarterly earnings will post 10.05% year-over-year. Quarterly sales are estimated to grow 14.22% in year-over-year returns.
The shares outstanding are 190.76M, and float is at 188.34M with Short Float at 2.37%.
The top institutional shareholder in the company is BLACKROCK INC. with over 22.74 million shares valued at $1.87 billion. The investor’s holdings represent 12.0394 of the BMRN Shares outstanding. As of 2024-06-30, the second largest holder is VANGUARD GROUP INC with 18.99 million shares valued at $1.56 billion to account for 10.0569 of the shares outstanding. The other top investors are PRIMECAP MANAGEMENT CO/CA/ which holds 18.79 million shares representing 9.8836 and valued at over $1.55 billion, while DODGE & COX holds 7.3274 of the shares totaling 13.93 million with a market value of $1.15 billion.
Biomarin Pharmaceutical Inc (BMRN) Insider Activity
Biomarin Pharmaceutical Inc disclosed in a document filed with the SEC on Feb 24 ’25 that Burkhart Erin (GVP, Chief Accounting Officer) sold a total of 1,344 shares of the company’s common stock. The trade occurred on Feb 24 ’25 and was made at $68.38 per share for $91903.0. Following the transaction, the insider now directly holds 13105.0 shares of the BMRN stock.
Still, SEC filings show that on Feb 24 ’25, Burkhart Erin (Officer) Proposed Sale 1,344 shares at an average price of $68.38 for $91903.0. The insider now directly holds shares of Biomarin Pharmaceutical Inc (BMRN).
